ArticleFrontiers in medicine2026
Guizhi-Shaoyao-Zhimu decoction alleviates gastrointestinal acute graft-vs.-host disease and suppresses FGF2/PI3K/Akt signaling: insights from network pharmacology, WGCNA, molecular docking, and animal experiment.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the potential preventive effects of Guizhi-Shaoyao-Zhimu Decoction (GSZD) on gastrointestinal acute graft-vs.-host disease (GI-aGVHD) and explore its potential mechanisms. Methods: Bioactive compounds and putative targets of GSZD were identified by network pharmacology. aGVHD-associated genes were retrieved from public databases, and gut damage-associated genes were identified by integrating differential expression analysis and WGCNA of two public transcriptomic datasets. Protein-protein interaction network construction, enrichment analyses, and molecular docking were performed. The effects of GSZD and the potential involvement of FGF2/PI3K/Akt signaling pathway were assessed in an aGVHD mouse model. Results: A total of 183 candidate compounds and 705 GSZD targets were identified. Database mining and transcriptomic analyses identified 816 aGVHD-associated genes and 161 gut damage-associated genes. Intersection analysis revealed 109 targets shared between GSZD and aGVHD, and 11 targets shared between GSZD and aGVHD gut damage. Network and enrichment analyses highlighted AKT1, FGF2, and PI3K/Akt signaling pathway for further evaluation. Exploratory molecular docking provided predicted rankings for 31 AKT1-compound pairs and two FGF2-compound pairs. Conclusion: GSZD showed preventive effects against GI-aGVHD in a murine aGVHD model. These effects were accompanied by attenuated inflammatory responses and reduced FGF2/PI3K/Akt signaling, suggesting that this axis may contribute to the protective effects of GSZD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.